Osimertinib
Targeted pill for EGFR-mutated lung cancer.
- Starts working
- Varies
- Half-life
- About 48 hours
- In use since
- 2015
- Pregnancy
- Usually avoided
Overview
Osimertinib targets EGFR mutations found in about 15% of lung cancers in Western countries and up to half in East Asian non-smokers. It works in the brain too and is used after surgery and in advanced disease.
Conditions it's used for
How it works
Blocks a faulty growth switch in some lung cancers.
Osimertinib belongs to the Tyrosine kinase inhibitors. How Tyrosine kinase inhibitors work: block a faulty 'on switch' protein that a cancer depends on.
Uses
- EGFR-mutated non-small cell lung cancer (advanced and after surgery)
Available as: tablet.
Typical dose
- Adults
- 80 mg once a day.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Diarrhoea
- Rash
- Dry skin
- Nail infections
Serious — get medical help
Uncommon, but need prompt attention
- Lung inflammation
- QT prolongation
- Heart failure
Warnings
- Report new cough or breathlessness
Interactions
- Strong CYP3A4 inducers — avoid
- QT-prolonging drugs
Other medicines in the atlas that need care with Osimertinib, grouped by the reason:
High risk of dangerous heart rhythmMajorWith Amiodarone, Methadone
Both medicines prolong the QT interval; with a strongly QT-prolonging drug, torsades de pointes becomes a real risk.
What's usually done: Avoid where possible. If combined, check an ECG and keep potassium and magnesium normal.
Additive QT prolongationModerateWith Amisulpride, Amitriptyline, Artemether–lumefantrine, Azithromycin, Bedaquiline and 35 more
Both medicines can lengthen the QT interval. The risk is higher with heart disease, low potassium or magnesium, older age and female sex.
What's usually done: Often acceptable in people without risk factors; an ECG may be advised. Report palpitations or fainting.
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more
Enzyme induction lowers levels of this medicine, which may stop it working.
What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.
Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Higher rhythm riskModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Some CYP3A4 inhibitors raise concentrations of QT-prolonging medicines, adding to the risk of torsades and fainting.
What's usually done: Avoid high-risk combinations where possible; review the specific medicine and consider ECG monitoring.
Pregnancy and breastfeeding
Usually avoided
Contraception needed.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Tagrisso
- United Kingdom
- Tagrisso
- India
- Tagrisso
- Australia
- Tagrisso
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
How do I know if I have an EGFR mutation?
A biopsy or blood test checks the tumour's genes; it's standard for non-squamous lung cancer.
Do I need a prescription for Osimertinib?
Yes — Osimertinib is prescription-only in most countries.
Can I take Osimertinib during pregnancy?
Usually avoided. Contraception needed. Always check with a doctor or midwife.
Related medicines
Imatinib
Targeted pill that turned a deadly leukaemia into a manageable condition.
RxWHOTyrosine kinase inhibitorsPembrolizumab
Immunotherapy for many cancers — the world's top-selling medicine.
RxWHOImmune checkpoint inhibitorsCisplatin
Platinum chemotherapy that made testicular cancer curable.
RxWHOPlatinum chemotherapyErlotinib
EGFR tablet for lung cancers with EGFR mutations.
RxWHOTyrosine kinase inhibitorsGefitinib
First-generation EGFR tablet for mutated lung cancer.
RxWHOTyrosine kinase inhibitorsSorafenib
Multi-kinase tablet for liver, kidney and thyroid cancers.
RxTyrosine kinase inhibitors
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — L01EB04
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.